Codelivery of Anticancer Drug and Photosensitizer by PEGylated Graphene Oxide and Cell Penetrating Peptide Enhanced Tumor-Suppressing Effect on Osteosarcoma

Zhang, Yifei; Wu, Yunfeng; Lan, Taijin; Chen, Yao; Su, Shihong

doi:10.3389/fmolb.2020.618896

Cited by 6 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, systems that incorporate combination therapies exhibit some of the strongest anticancer effects due to the synergistic effects of PTT, PDT, single-drug and combination chemotherapy, or immunotherapy [ 67 , 129 , 169 , 190 ]. CNMs are the perfect class of nanoparticles for this approach, as they are easy to modify both covalently and noncovalently, with a range of functionalisation approaches available, allowing for the attachment of many different therapeutic agents.…”

Section: Discussionmentioning

confidence: 99%

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

2023

View full text Add to dashboard Cite

Carbon nanomaterials (CNMs) are an incredibly versatile class of materials that can be used as scaffolds to construct anticancer nanocarrier systems. The ease of chemical functionalisation, biocompatibility, and intrinsic therapeutic capabilities of many of these nanoparticles can be leveraged to design effective anticancer systems. This article is the first comprehensive review of CNM-based nanocarrier systems that incorporate approved chemotherapy drugs, and many different types of CNMs and chemotherapy agents are discussed. Almost 200 examples of these nanocarrier systems have been analysed and compiled into a database. The entries are organised by anticancer drug type, and the composition, drug loading/release metrics, and experimental results from these systems have been compiled. Our analysis reveals graphene, and particularly graphene oxide (GO), as the most frequently employed CNM, with carbon nanotubes and carbon dots following in popularity. Moreover, the database encompasses various chemotherapeutic agents, with antimicrotubule agents being the most common payload due to their compatibility with CNM surfaces. The benefits of the identified systems are discussed, and the factors affecting their efficacy are detailed.

show abstract

Section: Discussionmentioning

confidence: 99%

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

2023

View full text Add to dashboard Cite

show abstract

“…Cell-penetrating peptides (CPPs), low-molecular-weight peptides possessing membrane translocation abilities, serve as carriers facilitating the cellu-lar entry of various large molecules [44]. Zhang et al [45] combined these aforementioned materials, using polyethylene glycol (PEG) linkage to produce cell-penetrating peptide (CPP)-modified graphene oxide (pGO). They loaded HPPH and EPI onto this material, forming HPPH/EPI/CPP-pGO, significantly enhancing drug delivery to tumor tissues.…”

Section: Combinatorial Treatment Of Hpph and Other Materialsmentioning

confidence: 99%

Recent Advances in the HPPH-Based Third-Generation Photodynamic Agents in Biomedical Applications

Fan,

Jiang,

Xiong

et al. 2023

IJMS

View full text Add to dashboard Cite

Photodynamic therapy has emerged as a recognized anti-tumor treatment involving three fundamental elements: photosensitizers, light, and reactive oxygen species. Enhancing the effectiveness of photosensitizers remains the primary avenue for improving the biological therapeutic outcomes of PDT. Through three generations of development, HPPH is a 2-(1-hexyloxyethyl)-2-devinyl derivative of pyropheophorbide-α, representing a second-generation photosensitizer already undergoing clinical trials for various tumors. The evolution toward third-generation photosensitizers based on HPPH involves structural modifications for multimodal applications and the combination of multifunctional compounds, leading to improved imaging localization and superior anti-tumor effects. While research into third-generation HPPH is beneficial for advancing PDT treatment, equal attention should also be directed toward the other two essential elements and personalized diagnosis and treatment methodologies.

show abstract

“…In vitro drug release of free HPPH and nanoparticles was performed using a dialysis membrane technique [35]. The nanoparticles were transferred to dialysis membrane tubes (MWCO12 kDa) (Himedia, India).…”

Section: In Vitro Drug Release Study Of Hpph-loaded Nanoparticlesmentioning

confidence: 99%

Development and validation of a stability‐indicating reversed‐phase–high‐performance liquid chromatography method for quantification of 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a from lipid‐polymeric hybrid nanoparticles

Pradhan

Dubey

Puri

et al. 2022

Separation Science Plus

View full text Add to dashboard Cite

2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a is a second‐generation, lipophilic, chlorin‐based photosensitizer currently used for various types of solid cancer including breast, esophageal, neck, and head cancer, etc. The aim of the present work was to develop a sensitive and robust reversed‐phase–high‐performance liquid chromatography–ultraviolet detection method for the determination of 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a to explore in vitro‐based applications including encapsulation, loading, drug release, and stability studies, and also could be utilized for the selective analysis of 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a from developed lipid polymer hybrid nanoparticle. The developed reversed‐phase–high‐performance liquid chromatography–ultraviolet detection method was validated in terms of linearity, accuracy, precision, stability, and robustness as per standard guidelines. The developed method exhibited linearity ranging from 50 to 2000 ng/ml with an R2 value of 0.999. The limit of detection and limit of quantitation value of the developed method was found to be 14.03 and 42.80 ng/ml, respectively. Also, degradation studies revealed that 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a degraded quickly under basic conditions compared to other stability conditions (i.e., acidic, oxidative, temperature, etc.). Furthermore, the developed drug‐loaded lipid polymer hybrid nanoparticle showed an average size of 123.03 nm (polydispersity index = 0.253) with an encapsulation efficiency of 70.23%. Cell cytotoxicity assay of lipid polymer hybrid nanoparticle showed significant cancer cell death equivalent to 2‐fold higher than the free drug. In conclusion, the developed reversed‐phase–high‐performance liquid chromatography–ultraviolet detection analytical method was found to be sensitive and reliable for the determination of free 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a and 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a content in loaded lipid polymer hybrid nanoparticle. Thereby, opening the avenues for future research to explore the detailed physiochemical and formulation designing for the 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a.

show abstract

Codelivery of Anticancer Drug and Photosensitizer by PEGylated Graphene Oxide and Cell Penetrating Peptide Enhanced Tumor-Suppressing Effect on Osteosarcoma

Cited by 6 publications

References 30 publications

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

Recent Advances in the HPPH-Based Third-Generation Photodynamic Agents in Biomedical Applications

Development and validation of a stability‐indicating reversed‐phase–high‐performance liquid chromatography method for quantification of 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a from lipid‐polymeric hybrid nanoparticles

Contact Info

Product

Resources

About